Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS9 | O00182 | 1/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.42 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15520935 | 1.00 | LGALS9 (0.42) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL14268495 | 1.00 | LGALS9 (0.42) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL7361176 | 1.00 | LGALS9 (0.42) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL16815111 | 1.00 | LGALS9 (0.42) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL5035219 | 1.00 | LGALS9 (0.42) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL4826392 | 1.00 | LGALS9 (0.42) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL14293980 | 1.00 | LGALS9 (0.42) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL19646640 | 0.89 | TSHR (0.47) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL12618658 | 0.89 | TSHR (0.47) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL17682036 | 0.89 | TSHR (0.47) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435816-B2 | Synthesis of solanum glycosides | GLYCOMED SCIENCES (KY) | 2008-10-14 | — | — | US | claimed |
| EP-1421100-B1 | CHEMICAL SYNTHESIS OF SOLAMARGINE | GLYCOMED SCIENCES LTD (KY) | 2008-07-09 | — | — | EP | claimed |
| US-20080039628-A1 | Synthesis of Solanum Glycosides | GLYCOMED SCIENCES (KY) | 2008-02-14 | — | — | US | claimed |
| EP-1618122-A1 | SYNTHESIS OF SOLANUM GLYCOSIDES | GlycoMed Sciences (UK) Limited, c/o Consolidated Capital Limited (GB) | 2006-01-25 | — | — | EP | claimed |
| US-20040259814-A1 | Synthesis of solanum glycosides | GLYCOMED SCIENCES LIMITED (KY) | 2004-12-23 | — | — | US | claimed |
| WO-2004096830-A1 | SYNTHESIS OF SOLANUM GLYCOSIDES | GLYCOMED SCIENCES (UK) LIMITED (GB) | 2004-11-11 | — | — | WO | claimed |
| EP-1421100-A1 | CHEMICAL SYNTHESIS OF SOLAMARGINE | GlycoMed Sciences Limited (AU) | 2004-05-26 | — | — | EP | claimed |
| WO-2003018604-A1 | SYNTHESIS OF SOLANUM GLYCOSIDES | GLYCOMED SCIENCES LIMITED (AU) | 2003-03-06 | — | — | WO | claimed |
| US-20040259814-A1 | Synthesis of solanum glycosides | GLYCOMED SCIENCES LIMITED (KY) | 2004-12-23 | — | — | US | disclosed |
| EP-0030331-B1 | C-3-BRANCHED CARDENOLIDE GLYCOSIDES, THEIR PREPARATION AND USE | BASF Aktiengesellschaft (DE) | 1983-06-29 | — | — | EP | disclosed |
| EP-0030331-A1 | C-3-branched cardenolide glycosides, their preparation and use | BASF Aktiengesellschaft (DE) | 1981-06-17 | — | — | EP | disclosed |
| US-4252970-A | MULTISTEP PROCESS, ONE STEP IS DESULFONATION OF 6-SULFONYLNEAMINES TO FORM 5,6-DIDEOXY-5-OXONEAMINES | THE UPJOHN COMPANY (US) | 1981-02-24 | — | — | US | disclosed |
| US-4242332-A | 4,5-Methano-bufadienolide-rhamnosides, their preparation, and drugs containing these compounds | BASF AKTIENGESELLSCHAFT (DE) | 1980-12-30 | — | — | US | disclosed |
| US-4232148-A | ANTIBACTERIAL | THE UPJOHN COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| EP-0009232-A1 | 4,5-Methano-bufadienolide-rhamnosides, process for their preparation and medicines containing them | BASF Aktiengesellschaft (DE) | 1980-04-02 | — | — | EP | disclosed |
| US-4169197-A | ANTIBIOTICS | THE UPJOHN COMPANY (US) | 1979-09-25 | — | — | US | disclosed |
| US-4038478-A | ANTIBACTERIAL AGENTS | THE UPJOHN COMPANY (US) | 1977-07-26 | — | — | US | disclosed |
| US-3996205-A | BACTERICIDES | THE UPJOHN COMPANY (US) | 1976-12-07 | — | — | US | disclosed |
| US-3984393-A | BACTERICIDES | THE UPJOHN COMPANY (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259814-A1 | Synthesis of solanum glycosides | GALE, MGAM, STS | LGALS9 412/4885LGALS1 411/4885LGALS3 295/4885 |
| US-20080039628-A1 | Synthesis of Solanum Glycosides | B3GNT2, ST6GAL1, ST3GAL3 | LGALS9 2362/4885LGALS1 2120/4885LGALS3 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.